

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/192355 A1

(51) International Patent Classification:
A61K 9/06 (2006.01) *A61K 9/113* (2006.01)

(21) International Application Number:
PCT/US2024/020171

(22) International Filing Date:
15 March 2024 (15.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/490,470 15 March 2023 (15.03.2023) US
63/462,860 28 April 2023 (28.04.2023) US
63/466,979 16 May 2023 (16.05.2023) US
63/543,645 11 October 2023 (11.10.2023) US
63/618,518 08 January 2024 (08.01.2024) US

(71) Applicant: **DERMAVANT SCIENCES GMBH**
[CH/CH]; Viaduktstrasse 8, 4051 Basel (CH).

(72) Inventors: **MCHALE, Kimberly Ann**; Durham, North Carolina 27704 (US). **PISCITELLI, Stephen C.**; 1822 Patrick Henry Lane, Hillsborough, North Carolina 27278 (US). **RUBENSTEIN, David Scott**; Chapel Hill, North Carolina 27516 (US).

(74) Agent: **PATANE, Michael A.** et al.; DLA PIPER LLP (US), 1650 Market Street, Suite 5000, Philadelphia, Pennsylvania 19103-7348 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHODS OF TREATING ATOPIC DERMATITIS USING TAPINAROF




FIG. 2

(57) Abstract: Disclosed is composition and a method for treating atopic dermatitis by applying a 1.0% tapinarof topical cream to the affected area of a subject once daily for a minimum of 8 weeks. The treatment results in a significant improvement in the vIGA-AD score, achieving at least a 2-grade improvement from baseline and a final score of 0. Additionally, a reduction of at least 4 points in the PP-NRS score is observed during the treatment period. In some instances, the method ensures that the plasma concentration of tapinarof remains below 50 pg/mL throughout the application of the topical cream, providing an effective and safe treatment for atopic dermatitis.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))